Hepatic Cell News 2.42 November 2, 2018 | |
| |
TOP STORYDown-regulation of zinc finger CCCH-type containing 14 (ZC3H14) was significantly associated with poor outcomes of patients with hepatocellular carcinoma (HCC). Over-expression of ZC3H14 in HCC cell lines significantly suppressed HCC cells growth in vitro and metastasis in vivo. In contrast, RNA interference silencing of ZC3H14 inhibited its tumor suppressive function. [Carcinogenesis] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Activating transcription factor 3 (ATF3) overexpression vector and shRNAs were transfected into hepatocellular carcinoma cancer cells to upregulate or downregulate ATF3 expression. In vitro and in vivo assays were performed to investigate the functional role of ATF3 in hepatocellular carcinoma. [J Exp Clin Cancer Res] Full Article Comparative Glycomics Study of Cell-Surface N-Glycomes of HepG2 versus LO2 Cell Lines. Scientists report comparative N-glycomics study of cell-surface N-glycans of the hepatocellular carcinoma HepG2 cells vs the normal liver LO2 cells. With sequential trypsin digestion of proteins, C18 depletion of peptides without glycosylation, PNGase F digestion of N-glycopeptides, PGC enrichment of N-glycans, CH3I permethylation of the enriched N-glycans, cell-surface N-glycomes of the HepG2 and LO2 cells were analyzed using C18-RPLC-MS/MS. [J Proteome Res] Abstract | Graphical Abstract Through screening, researchers identified oxytetracycline, which showed significant inhibition activity of liver cancer stem cell (LCSC) population without damage on hepatocytes. Treating of spheroid-forming LCSCs with oxytetracycline effectively decreased the spheroid formation and the CD133+ cell population. [Sci Rep] Full Article Functional Polarization of Human Hepatoma HepaRG Cells in Response to Forskolin Forskolin (FSK) used at 50µM for three days was found to promote polarization of high density-plated HepaRG cells, i.e., it markedly enhanced the formation of functional biliary canaliculi structures. FSK-treated HepaRG cells displayed enhanced activities of CYP3A4, NTCP and OATPs when compared to untreated cells. [Sci Rep] Full Article Cell apoptosis, viability, migration, and invasion were evaluated by means of flow cytometry, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide, and transwell assays, respectively. Hepatocellular carcinoma (HCC) xenograft in nude mice was performed to measure HCC tumor growth. miR-221 was found to be highly expressed but SOCS3 was poorly expressed in HCC tissues. [J Cell Physiol] Abstract High mobility group box 1 protein (HMGB1) silencing was found to significantly increase tumor cells viability with significant decrease of pro-apoptotic proteins, also antiapoptotic protein Bcl2 was significantly up-regulated, which suggests a possible role in restricting apoptosis. HMGB1 knocked down was found to inhibit Stat3 phosphorylation and significantly affect NFkB p65/Cox2 expression which suggests a link between HMGB1 and Stat3 activation. [Biofactors] Abstract Downregulation of FER1L4 in hepatocellular carcinoma tissues and cells was demonstrated by qRT-PCR analysis. FER1L4 overexpression evidently attenuated the cell proliferation, migration and invasion, but prompted cell apoptosis. Western blot assays revealed that PII3K/AKT signal pathway were involved in mediating the progression regulation role of FER1L4 in hepatocellular carcinoma cells. [J Cell Biochem] Abstract Investigators showed an under-regulated expression of FOXP3 in liver neoplasm tissues from qRT-PCR results. Overexpression of FOXP3 contributed to cell apoptosis as well as suppressed tumor cells’ proliferation. miR-198 was detected to be highly expressed in FOXP3-overexpressing HepG2 cells. [Cancer Med] Full Article Researchers found that hepatocellular carcinoma (HCC) cell line responsiveness to Dasatinib varied significantly. There was no correlation between c-Myc expression and IC50 to Dasatinib. In c-Myc-induced HCC in mice, tumors continued to grow despite Dasatinib treatment, although the eventual tumor burden was lower in Dasatinib treatment cohort. [Cancer Med] Full Article Differentially expressed circRNAs were identified, and RT-qPCR was used to verify a subset of the differentially expressed circRNAs (target genes). At the same time, mouse oxidative stress injury, macrophage inflammation, and hepatic stellate cell activation models were established, and the expression of target circRNA in the above cells was measured by RT-qPCR. [Hepatol Res] Abstract | |
| |
REVIEWSIn this review, researchers discuss the biologic foundations supporting the development of immune checkpoint inhibitors (ICPI) across the advancing stages of hepatocellular carcinoma, focusing in particular on the proposal of a rational positioning of ICPI across the various Barcelona-Clinic Liver Cancer stages of the disease. [Hepatology] Abstract Lipid Mediators of Liver Injury in Nonalcoholic Fatty Liver Disease Authors focus on the recent data on the mechanisms of nonalcoholic fatty liver disease (NASH) focusing on lipid mediators and their potential as therapeutic targets in NASH. [Am J Physiol Gastrointest Liver Physiol] Abstract Visit our reviews page to see a complete list of reviews in the hepatic cell research field. | |
| |
INDUSTRY NEWSNovartis Announces Clinical Collaboration with Pfizer to Advance the Treatment of NASH Novartis announced that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase Inhibitor, a Diacylglycerol O-Acyltransferase 2 Inhibitor and a Ketohexokinase Inhibitor. [Novartis AG] Press Release Innovate Biopharmaceuticals, Inc. announced a potential expanded use for its lead agent, larazotide acetate, with topline preclinical data demonstrating proof-of-concept in an established model of nonalcoholic steatohepatitis (NASH). Innovate intends to launch a clinical program in NASH with a phase II trial in 2019. [Innovate Biopharmaceuticals] Press Release Nash Pharmaceuticals Inc., announced that its lead compound for non-alcoholic steatohepatitis (NASH) NP-160 showed positive results in a recently completed study investigating its therapeutic effects in the widely used STAM™ mouse model from SMC Laboratories. NP-160 is one of a number of already approved compounds that Nash Pharma has been screening for new therapeutic uses as part of its drug repurposing strategy. [Breathtec Biomedical Inc] Press Release Celerion Expands NASH Biomarkers Services with the Implementation of FibroScan® Celerion, announced the implementation of FibroScan® to complement a suite of soluble biomarkers Celerion has validated to support nonalcoholic steatohepatitis (NASH) clinical studies. [Celerion] Press Release | |
| |
POLICY NEWSRecord Number of Monkeys Being Used in U.S. Research The number of monkeys used in U.S. biomedical research reached an all-time high last year, according to data released in late September by the United States Department of Agriculture. [ScienceInsider] Editorial Drug Companies Try to Catch the Rising Wave of RNAi Medicines Less than two months after the FDA approved the first-ever drug that uses a Nobel-winning technique to mute disease-causing genes, the pharmaceutical industry is already looking for a piece of the next one. [STAT News] Editorial
| |
EVENTSNEW Obesity and NAFLD: Mechanisms and Therapeutics Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Post Doctoral Fellowship – Liver Biology and Pathophysiology (Johns Hopkins University) Postdoctoral Position – Molecular & Integrative Physiology (University of Michigan) Principal Scientific Officer – Liver Regeneration & Cancer (Cancer Research UK Beatson Institute) Postdoctoral Researcher – RNA-Targeting Therapeutics (Ionis Pharmaceuticals, Inc.) Postdoctoral Fellow – Inflammation/Innate Immunity/Cell Signaling (University of Colorado Denver) Faculty Position – Biochemistry and/or Biophysics (University of Kansas Medical Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Hepatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|